Agrylin, Xagrid(anagrelide)
Agrylin, Anagrelide, Xagrid (anagrelide) is a small molecule pharmaceutical. Anagrelide was first approved as Agrylin on 1997-03-14. It is used to treat polycythemia vera and thrombocytosis in the USA. It has been approved in Europe to treat essential thrombocythemia. The pharmaceutical is active against cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area | MeSH |
|---|---|
| neoplasms | D009369 |
| hemic and lymphatic diseases | D006425 |
Trade Name
FDA
EMA
Agrylin (generic drugs available since 2005-04-18)
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| agrylin | New Drug Application | 2023-12-29 |
| anagrelide | ANDA | 2022-10-21 |
| anagrelide hydrochloride | ANDA | 2022-05-04 |
Indications
FDA
EMA
Indication | Ontology | MeSH | ICD-10 |
|---|---|---|---|
| polycythemia vera | — | D011087 | D45 |
| thrombocytosis | — | D013922 | D75.83 |
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
Code | Description |
|---|---|
| G9531 | Patient has documentation of ventricular shunt, brain tumor, multisystem trauma, or is currently taking an antiplatelet medication including: abciximab, anagrelide, cangrelor, cilostazol, clopidogrel, dipyridamole, eptifibatide, prasugrel, ticlopidine, ticagrelor, tirofiban, or vorapaxar |
Clinical
Clinical Trials
29 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Essential thrombocythemia | D013920 | — | D47.3 | — | 3 | 8 | 2 | 4 | 16 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Polycythemia vera | D011087 | — | D45 | — | 1 | 2 | — | — | 3 |
| Primary myelofibrosis | D055728 | — | D47.4 | — | 1 | 1 | — | — | 2 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | — | 1 | — | — | — | 1 |
| Thrombocytosis | D013922 | HP_0001894 | D75.83 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 4 | — | — | — | — | 4 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Anagrelide |
| INN | anagrelide |
| Description | Anagrelide (Agrylin/Xagrid, Shire and Thromboreductin, AOP Orphan Pharmaceuticals AG) is a drug used for the treatment of essential thrombocytosis (also known as essential thrombocythemia), or overproduction of blood platelets. It also has been used in the treatment of chronic myeloid leukemia.
|
| Classification | Small molecule |
| Drug class | platelet aggregation inhibitors, primarily platelet P2Y12 receptor antagonists |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | O=C1CN2Cc3c(ccc(Cl)c3Cl)N=C2N1 |
Identifiers
| PDB | — |
| CAS-ID | 68475-42-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL760 |
| ChEBI ID | 142290 |
| PubChem CID | 2182 |
| DrugBank | DB00261 |
| UNII ID | K9X45X0051 (ChemIDplus, GSRS) |
Target
Agency Approved
PDE3A
PDE3A
Organism
Homo sapiens
Gene name
PDE3A
Gene synonyms
NCBI Gene ID
Protein name
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A
Protein synonyms
cAMP phosphodiesterase, myocardial cGMP-inhibited, cGI-PDE, CGI-PDE A, cGMP-inhibited 3',5'-cyclic phosphodiesterase A, cGMP-inhibited cAMP phosphodiesterase, Cyclic GMP-inhibited phosphodiesterase A, phosphodiesterase 3A, cGMP-inhibited
Uniprot ID
Mouse ortholog
Pde3a (54611)
cGMP-inhibited 3',5'-cyclic phosphodiesterase 3A (Q9Z0X4)
Alternate
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
Xagrid – Shire
Mock data
Subscribe for the real data
Subscribe for the real data
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Estimated US medical usage
Anagrelide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,018 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,836 adverse events reported
View more details
© 2020-2023 Collaborative Drug Discovery Inc. (CDD) | Terms of Use